Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Finlay

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Frontiers in Pharmacology|April 27, 2019
Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-DependenceMikkel Søes Ibsen, David B Finlay, Monica Patel, et al.
British Journal of Pharmacology|June 4, 2024
Positive allosteric modulation of the cannabinoid CB<sub>1</sub> receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kineticsHayley M Green, Jamie J Manning, Ian R Greig, et al.
Methods in Enzymology|July 29, 2017
Real-Time Measurement of Cannabinoid Receptor-Mediated cAMP SignalingMorag R Hunter, David B Finlay, Christa E Macdonald, et al.
ACS Pharmacology & Translational Science|December 16, 2022
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1<i>H</i>-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?Hayley M Green, David B Finlay, Ruth A Ross, et al.
British Journal of Pharmacology|November 23, 2021
Delineating the interactions between the cannabinoid CB<sub>2</sub> receptor and its regulatory effectors; β-arrestins and GPCR kinasesMonica Patel, Christoph Matti, Natasha L Grimsey, et al.
Biochemical Pharmacology|February 24, 2020
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonistsMonica Patel, Jamie J Manning, David B Finlay, et al.
British Journal of Pharmacology|April 21, 2023
RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB<sub>1</sub>, CB<sub>2</sub>, GPR18 and GPR55 cannabinoid receptorsNathaniel A K Glenn, David B Finlay, Emma R Carruthers, et al.
British Journal of Pharmacology|May 19, 2017
Gα<sub>s</sub> signalling of the CB<sub>1</sub> receptor and the influence of receptor numberDavid B Finlay, Erin E Cawston, Natasha L Grimsey, et al.
Forensic Toxicology|January 18, 2023
Characterisation of AMB-FUBINACA metabolism and CB<sub>1</sub>-mediated activity of its acid metaboliteHunter D J Webb, David B Finlay, Shuli Chen, et al.
ACS Chemical Neuroscience|September 13, 2019
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACADavid B Finlay, Jamie J Manning, Mikkel Søes Ibsen, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|April 27, 2019
Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-DependenceMikkel Søes Ibsen, David B Finlay, Monica Patel, et al.
British Journal of Pharmacology|June 4, 2024
Positive allosteric modulation of the cannabinoid CB<sub>1</sub> receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kineticsHayley M Green, Jamie J Manning, Ian R Greig, et al.
Methods in Enzymology|July 29, 2017
Real-Time Measurement of Cannabinoid Receptor-Mediated cAMP SignalingMorag R Hunter, David B Finlay, Christa E Macdonald, et al.
ACS Pharmacology & Translational Science|December 16, 2022
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1<i>H</i>-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?Hayley M Green, David B Finlay, Ruth A Ross, et al.
British Journal of Pharmacology|November 23, 2021
Delineating the interactions between the cannabinoid CB<sub>2</sub> receptor and its regulatory effectors; β-arrestins and GPCR kinasesMonica Patel, Christoph Matti, Natasha L Grimsey, et al.
Biochemical Pharmacology|February 24, 2020
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonistsMonica Patel, Jamie J Manning, David B Finlay, et al.
British Journal of Pharmacology|April 21, 2023
RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB<sub>1</sub>, CB<sub>2</sub>, GPR18 and GPR55 cannabinoid receptorsNathaniel A K Glenn, David B Finlay, Emma R Carruthers, et al.
British Journal of Pharmacology|May 19, 2017
Gα<sub>s</sub> signalling of the CB<sub>1</sub> receptor and the influence of receptor numberDavid B Finlay, Erin E Cawston, Natasha L Grimsey, et al.
Forensic Toxicology|January 18, 2023
Characterisation of AMB-FUBINACA metabolism and CB<sub>1</sub>-mediated activity of its acid metaboliteHunter D J Webb, David B Finlay, Shuli Chen, et al.
ACS Chemical Neuroscience|September 13, 2019
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACADavid B Finlay, Jamie J Manning, Mikkel Søes Ibsen, et al.
Pageof 4